Modelling and Simulation in the Development and use of Anti-Cancer Agents: An Underused Tool? Ferdinand RomboutLeon Aaronsinvited COST B15 Experts OriginalPaper 19 July 2005 Pages: 419 - 440
Pharmacokinetic/Pharmacodynamic Modellingof GnRH Antagonist Degarelix: A Comparisonof the Non-linear Mixed-Effects Programs NONMEM and NLME Christoffer W. TornøeHenrik AgersøE. Niclas Jonsson OriginalPaper 19 July 2005 Pages: 441 - 461
Population Pharmacokinetic Modeling of Subcutaneously Administered Etanercept in Patients with Psoriasis Ivan NestorovRalph ZitnikThomas Ludden OriginalPaper 19 July 2005 Pages: 463 - 490